Overview
Recent advances in oncology have reshaped the treatment landscape for colorectal cancer, particularly for patients with microsatellite instability-high (MSI‑H) or mismatch repair‑deficient (dMMR) tumors. A landmark UK‑led trial demonstrated that administering the programmed cell death‑1 (PD‑1) inhibitor pembrolizumab for just nine weeks before surgery can lead to remarkably durable remissions. Patients in that study remained cancer‑free for nearly three years—a result that challenges the traditional paradigm of upfront surgery followed by months of chemotherapy. This guide breaks down the neoadjuvant immunotherapy approach, from patient selection to post‑treatment monitoring, providing clinicians and informed patients with a clear, actionable roadmap.
Prerequisites
Before implementing this protocol, ensure the following foundational knowledge and resources are in place:
- Understanding of colorectal cancer staging (TNM system) and the concept of microsatellite instability (MSI).
- Familiarity with immunotherapy basics, especially PD‑1/PD‑L1 checkpoint inhibition.
- Access to molecular testing for MSI status or immunohistochemistry for mismatch repair (MMR) proteins.
- Multidisciplinary team (MDT) including medical oncologists, surgeons, radiologists, and pathologists.
- Infusion center capabilities for administering pembrolizumab.
Step‑by‑Step Instructions
Step 1: Patient Selection
Not every colorectal cancer patient is eligible. The key criterion is MSI‑High (MSI‑H) or dMMR status. Only about 15% of all colorectal cancers exhibit this phenotype, but it is more common in early‑stage, right‑sided, and mucinous tumors. Confirm with next‑generation sequencing (NGS) or immunohistochemistry for MLH1, MSH2, MSH6, and PMS2. Patients should also be candidates for curative‑intent surgery (i.e., resectable disease) and have no contraindications to immunotherapy (e.g., active autoimmune disorders requiring systemic immunosuppression).
Step 2: Treatment Planning
Coordinate with the surgical team to plan the timing. The protocol uses a nine‑week course of pembrolizumab, administered every three weeks (three doses). Before starting, inform patients about potential immune‑related adverse events (irAEs) and establish a baseline evaluation including blood counts, liver function, thyroid panel, and imaging (CT or MRI) to document tumor dimensions.
Step 3: Administration of Pembrolizumab
- Dose: 200 mg flat dose or 2 mg/kg (up to 200 mg) every three weeks.
- Infusion: Intravenous over 30 minutes. Monitor for infusion reactions.
- Schedule: Administer on days 1, 22, and 43 (weeks 1, 4, and 7).
- Premedication: Not routinely required; consider antihistamines if prior hypersensitivity.
During the nine‑week window, reassess the patient weekly for adverse events. Common irAEs include fatigue, rash, diarrhea (colitis), and hypothyroidism. Grade 3 or higher events may require dose delay or corticosteroids. The goal is to complete all three doses without compromising a safe surgical window.
Step 4: Surgery
Approximately two to four weeks after the last dose, proceed with curative‑intent resection. The wait allows for peak immune activation and maximal tumor shrinkage. Preoperative imaging should be repeated to assess response; a significant reduction in size or even radiographic complete response is possible. The surgical approach (laparoscopic vs. open) follows standard oncologic principles. Resect the primary tumor and any involved lymph nodes en bloc. Send the specimen for pathologic staging.
Step 5: Pathology Assessment
The pathologist should evaluate the resection specimen for:
- Pathologic complete response (pCR) — absence of viable tumor cells.
- Lymph node status — downsizing to ypN0 is a favorable indicator.
- Tumor regression grade — using a four‑ or five‑tier system.
In the landmark trial, a high proportion of patients achieved pCR, and those who did had outstanding long‑term outcomes.
Step 6: Postoperative Monitoring
After surgery, patients typically do not receive adjuvant chemotherapy if they achieved a meaningful response to neoadjuvant immunotherapy. Surveillance includes:
- Clinical exam and CEA level every three months for two years, then every six months for three years.
- CT scan of chest/abdomen/pelvis annually for three years.
- Colonoscopy at one year and then every three to five years.
Special attention to immune‑related late effects, such as endocrinopathies (hypothyroidism, adrenal insufficiency), which may persist. Manage as per standard guidelines.
Common Mistakes
Ignoring MSI/MMR Testing
The single most common error is to start pembrolizumab in a patient with microsatellite‑stable (MSS) or proficient MMR (pMMR) tumors. These derive minimal benefit. Always confirm MSI‑H/dMMR status before initiating therapy.
Prolonging Treatment Beyond Nine Weeks
Nine weeks was specifically chosen as a short burst; extending therapy may delay surgery and increase toxicity without proven benefit. Adhere to the protocol.
Inadequate Timing of Surgery
Operating too soon (<2 weeks after last dose) may miss maximal response; waiting too long (>6 weeks) risks tumor regrowth. Stick to the 2–4 week window.
Underestimating Immune‑Related Side Effects
Even short courses can cause severe colitis or pneumonitis. Have a low threshold for holding therapy and consulting specialists. Educate patients to report any new symptoms immediately.
Summary
The neoadjuvant use of pembrolizumab for nine weeks in MSI‑H/dMMR colorectal cancer represents a paradigm shift. It achieves high pathologic response rates and can extend disease‑free survival to nearly three years while sparing patients the toxicity of prolonged adjuvant chemotherapy. This guide outlines the essential steps from proper patient selection to vigilant monitoring, helping clinicians safely adopt this breakthrough. Early molecular testing is critical; the protocol is simple but demands careful timing and multidisciplinary coordination. With careful execution, many more patients can achieve long‑term cancer‑free survival without conventional chemotherapy.